Last reviewed · How we verify
Diabinese (CHLORPROPAMIDE)
Diabinese (Chlorpropamide) is a small molecule sulfonylurea that targets the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel in pancreatic beta cells. It was originally developed by Pfizer and remains under their ownership. Diabinese is used to treat type 2 diabetes mellitus by stimulating insulin release from the pancreas. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include hypoglycemia risk and potential interactions with other medications.
At a glance
| Generic name | CHLORPROPAMIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Sulfonylurea |
| Target | Sulfonylurea receptor 1, Kir6.2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1958 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Drug interactions
- ciprofloxacin
- gatifloxacin
- labetalol
- levofloxacin
- metoprolol
- nadolol
- norfloxacin
- ofloxacin
- penbutolol
- pindolol
- propranolol
- rifampicin
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Incretin-based Drugs and Pancreatic Cancer
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies (PHASE2)
- Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diabinese CI brief — competitive landscape report
- Diabinese updates RSS · CI watch RSS
- Pfizer portfolio CI